Sign in

    Kemp Doliver

    Research Analyst at Brookline Capital Markets

    Kemp Dolliver is the Director of Research and Senior Analyst at Brookline Capital Markets, specializing in healthcare sector research with deep coverage of innovative biopharmaceutical and medtech companies. He has covered companies such as Bellerophon Therapeutics (BLPH), delivering top-rated calls including a single-stock return of 355.5% and maintaining coverage on approximately 30 stocks with a diverse track record highlighted on platforms like TipRanks. Dolliver began his career in investment banking and portfolio management, including roles at Cowen, Avondale Partners, and Religare Capital before founding Cherrystone Hill Capital Management and joining Brookline; his work has been recognized four times in The Wall Street Journal’s “Best on the Street” survey. He holds a B.S. in Commerce from the University of Virginia’s McIntire School of Commerce, an MBA from UVA’s Darden School of Business, and serves on the McIntire Advisory Board.

    Kemp Doliver's questions to PROC leadership

    Kemp Doliver's questions to PROC leadership • Q2 2023

    Question

    Asked about progress on working capital accounts, board stability following a director's resignation, the status of the US operations in Florida, and details of a new debt agreement.

    Answer

    Progress on working capital is ongoing but has been delayed by customer pressures; initiatives are in place to improve it. The board is considered stable despite the resignation, which was attributed to impatience. The Florida facilities are advancing, with the Funtrition plant starting packing operations and the Softgel plant supporting R&D, with meaningful sales from both expected in 2024. A new debt agreement was signed, consolidating debt into a ~$60M club deal, extending maturity to six years, and shifting debt from short-term to long-term.

    Ask Fintool Equity Research AI